OmniAb Taps Amechi Nwachuku as Executive Vice President & Chief Operating Officer

OmniAb Inc., a provider of discovery research technology to enable the discovery of next-generation therapeutics, has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer (COO).

Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration, OmniAb’s proprietary high-throughput single B-cell screening platform.

“Amechi is a seasoned global leader whose extensive experience and perspectives will further strengthen our executive management team,” said Matt Foehr, President and CEO of OmniAb. “Throughout his career, Amechi has established a proven track record of commercial and operational excellence, consistently driving growth, capitalizing on market opportunities, and efficiently creating value.”

Experience

Nwachuku has more than 25 years of experience, including leading multi-billion-dollar global life sciences tools businesses, with responsibility for driving commercial strategy, sales, marketing and integrated operations.

Most recently, Nwachuku served as Vice President of Global Commercial Genetic Sciences at Thermo Fisher Scientific, and prior to that as Senior Vice President, Global Commercial, SCIEX at Danaher Corporation. He also held senior executive roles within the Beckman Coulter Diagnostics business at Danaher and international leadership positions at Johnson & Johnson Diabetes Care and Bayer.

Early in his career, he served as a management consultant at McKinsey & Company. He earned a Bachelor of Science in Chemical Engineering and his Master of Business Administration (MBA) from the Massachusetts Institute of Technology (MIT).